MoonLake Immunotherapeutics (MLTX) Expected to Announce Earnings on Wednesday

MoonLake Immunotherapeutics (NASDAQ:MLTX) is anticipated to announce its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect MoonLake Immunotherapeutics to post earnings of ($0.97) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 9:30 AM ET.

MoonLake Immunotherapeutics Trading Up 11.1%

NASDAQ MLTX opened at $17.52 on Wednesday. The company has a current ratio of 8.50, a quick ratio of 8.50 and a debt-to-equity ratio of 0.25. The stock has a 50-day moving average of $15.00 and a 200-day moving average of $24.82. The firm has a market cap of $1.13 billion, a PE ratio of -5.28 and a beta of 1.21. MoonLake Immunotherapeutics has a 1-year low of $5.95 and a 1-year high of $62.75.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Oppenheimer reiterated an “outperform” rating and set a $30.00 price target on shares of MoonLake Immunotherapeutics in a report on Thursday, November 6th. The Goldman Sachs Group downgraded shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and upped their price objective for the company from $8.00 to $10.00 in a research note on Wednesday, January 14th. UBS Group set a $24.00 target price on MoonLake Immunotherapeutics in a research note on Friday, January 9th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of MoonLake Immunotherapeutics in a research report on Tuesday, February 3rd. Finally, BTIG Research reiterated a “buy” rating and issued a $24.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $25.77.

Insider Buying and Selling

In other news, CEO Da Silva Jorge Santos sold 70,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $14.49, for a total value of $1,014,300.00. Following the completion of the transaction, the chief executive officer owned 2,878,577 shares of the company’s stock, valued at $41,710,580.73. The trade was a 2.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kristian Reich sold 72,908 shares of the stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $14.43, for a total transaction of $1,052,062.44. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 402,908 shares of company stock worth $5,987,162. Insiders own 12.05% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of MLTX. Geode Capital Management LLC grew its stake in MoonLake Immunotherapeutics by 0.9% during the second quarter. Geode Capital Management LLC now owns 59,553 shares of the company’s stock valued at $2,809,000 after acquiring an additional 559 shares in the last quarter. Squarepoint Ops LLC lifted its stake in shares of MoonLake Immunotherapeutics by 3.7% during the 2nd quarter. Squarepoint Ops LLC now owns 17,571 shares of the company’s stock worth $829,000 after acquiring an additional 629 shares during the last quarter. Russell Investments Group Ltd. boosted its position in MoonLake Immunotherapeutics by 45.4% in the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock valued at $45,000 after buying an additional 1,069 shares during the period. BNP Paribas Financial Markets increased its stake in shares of MoonLake Immunotherapeutics by 18.9% during the third quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock valued at $52,000 after buying an additional 1,158 shares during the period. Finally, Legal & General Group Plc increased its holdings in MoonLake Immunotherapeutics by 7.3% during the second quarter. Legal & General Group Plc now owns 20,905 shares of the company’s stock valued at $987,000 after buying an additional 1,425 shares during the period. Hedge funds and other institutional investors own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.